HomeCompareSOLCF vs ABBV

SOLCF vs ABBV: Dividend Comparison 2026

SOLCF yields 8695.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SOLCF wins by $13929748371684704.00M in total portfolio value
10 years
SOLCF
SOLCF
● Live price
8695.65%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13929748371684704.00M
Annual income
$13,621,597,319,643,141,000,000.00
Full SOLCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SOLCF vs ABBV

📍 SOLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSOLCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SOLCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SOLCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOLCF
Annual income on $10K today (after 15% tax)
$739,130.43/yr
After 10yr DRIP, annual income (after tax)
$11,578,357,721,696,670,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SOLCF beats the other by $11,578,357,721,696,670,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOLCF + ABBV for your $10,000?

SOLCF: 50%ABBV: 50%
100% ABBV50/50100% SOLCF
Portfolio after 10yr
$6964874185842352.00M
Annual income
$6,810,798,659,821,571,000,000.00/yr
Blended yield
97.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SOLCF
No analyst data
Altman Z
-29.3
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOLCF buys
0
ABBV buys
0
No recent congressional trades found for SOLCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSOLCFABBV
Forward yield8695.65%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$13929748371684704.00M$102.3K
Annual income after 10y$13,621,597,319,643,141,000,000.00$24,771.77
Total dividends collected$13909191686085094.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SOLCF vs ABBV ($10,000, DRIP)

YearSOLCF PortfolioSOLCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$880,265$869,565.22$11,550$430.00+$868.7KSOLCF
2$72,479,081$71,537,197.68$13,472$627.96+$72.47MSOLCF
3$5,582,425,377$5,504,872,759.55$15,906$926.08+$5582.41MSOLCF
4$402,227,280,623$396,254,085,470.10$19,071$1,382.55+$402227.26MSOLCF
5$27,113,623,759,164$26,683,240,568,897.10$23,302$2,095.81+$27113623.74MSOLCF
6$1,710,023,665,770,469$1,681,012,088,348,163.80$29,150$3,237.93+$1710023665.74MSOLCF
7$100,913,288,124,840,380$99,083,562,802,465,980.00$37,536$5,121.41+$100913288124.80MSOLCF
8$5,572,648,881,986,598,000$5,464,671,663,693,019,000.00$50,079$8,338.38+$5572648881986.55MSOLCF
9$287,991,637,422,019,740,000$282,028,903,118,294,060,000.00$69,753$14,065.80+$287991637422019.69MSOLCF
10$13,929,748,371,684,704,000,000$13,621,597,319,643,141,000,000.00$102,337$24,771.77+$13929748371684704.00MSOLCF

SOLCF vs ABBV: Complete Analysis 2026

SOLCFStock

SOL Global Investments Corp. is a private equity firm specializing in emerging growth. The firm primarily invests in blockchain infrastructure and digital asset sector. SOL Global Investments Corp. is based in Toronto, Canada.

Full SOLCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SOLCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOLCF vs SCHDSOLCF vs JEPISOLCF vs OSOLCF vs KOSOLCF vs MAINSOLCF vs JNJSOLCF vs MRKSOLCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.